Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.36 | N/A | -4.96% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.36 | N/A | -4.96% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on advancing their therapeutic developments. They acknowledged the EPS results but emphasized long-term goals.
Management expressed confidence in ongoing projects and future developments.
They highlighted the importance of their research pipeline despite the EPS miss.
Despite missing on EPS, Tango Therapeutics I saw a significant stock increase of 14.91%. This positive reaction may be attributed to management's optimistic outlook on their research pipeline and future projects, which investors found encouraging.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PLAINS ALL AMERICAN
May 9, 2025